---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-25-000009"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T10:29:35.395768+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Charles River Labs Q4 GAAP loss $(4.22) on $215M goodwill impairment; guides FY2025 revenue down 5.5-3.5%

## Summary
- Q4 revenue $1.00B (-1.1% YoY); non-GAAP EPS $2.66 (+8.1%); GAAP loss $(4.22) from $215M Biologics Solutions goodwill impairment.
- Full-year 2024 revenue $4.05B (-1.9%); non-GAAP EPS $10.32 (-3.3%); GAAP EPS $0.20 (-97.8%).
- DSA segment revenue down 3.6% organically; Manufacturing organic +2.1%; RMS organic -0.4% despite Noveprim acquisition.
- 2025 guidance: organic revenue decline 5.5% to 3.5%; non-GAAP EPS $9.10-$9.60; plans $350M stock repurchase.
- CEO cites ongoing biopharma client restructuring; expects stable-to-slightly improved biotech demand in 2025.

## SEC filing metadata
- accession: 0001100682-25-000009
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/0001100682-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/crl-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-25-000009
- JSON: https://secwatch.observer/filing/0001100682-25-000009.json
- Plain text: https://secwatch.observer/filing/0001100682-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.